Neumora Therapeutics (NMRA) Competitors $1.80 +0.09 (+5.26%) Closing price 02/21/2025 04:00 PM EasternExtended Trading$1.76 -0.04 (-2.44%) As of 02/21/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends NMRA vs. ETNB, GYRE, AUPH, NTLA, MRVI, ELVN, PAHC, ZYME, ABCL, and REPLShould you be buying Neumora Therapeutics stock or one of its competitors? The main competitors of Neumora Therapeutics include 89bio (ETNB), Gyre Therapeutics (GYRE), Aurinia Pharmaceuticals (AUPH), Intellia Therapeutics (NTLA), Maravai LifeSciences (MRVI), Enliven Therapeutics (ELVN), Phibro Animal Health (PAHC), Zymeworks (ZYME), AbCellera Biologics (ABCL), and Replimune Group (REPL). These companies are all part of the "pharmaceutical products" industry. Neumora Therapeutics vs. 89bio Gyre Therapeutics Aurinia Pharmaceuticals Intellia Therapeutics Maravai LifeSciences Enliven Therapeutics Phibro Animal Health Zymeworks AbCellera Biologics Replimune Group Neumora Therapeutics (NASDAQ:NMRA) and 89bio (NASDAQ:ETNB) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, institutional ownership, risk, dividends, community ranking, analyst recommendations, earnings and valuation. Which has preferable valuation and earnings, NMRA or ETNB? 89bio is trading at a lower price-to-earnings ratio than Neumora Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNeumora TherapeuticsN/AN/A-$235.93M-$1.87-0.9689bioN/AN/A-$142.19M-$2.91-3.81 Do analysts recommend NMRA or ETNB? Neumora Therapeutics currently has a consensus price target of $16.50, suggesting a potential upside of 816.67%. 89bio has a consensus price target of $31.43, suggesting a potential upside of 183.78%. Given Neumora Therapeutics' higher possible upside, research analysts clearly believe Neumora Therapeutics is more favorable than 89bio.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Neumora Therapeutics 0 Sell rating(s) 2 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.7189bio 0 Sell rating(s) 2 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.89 Does the media prefer NMRA or ETNB? In the previous week, Neumora Therapeutics had 26 more articles in the media than 89bio. MarketBeat recorded 30 mentions for Neumora Therapeutics and 4 mentions for 89bio. 89bio's average media sentiment score of 0.66 beat Neumora Therapeutics' score of 0.08 indicating that 89bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Neumora Therapeutics 4 Very Positive mention(s) 4 Positive mention(s) 20 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral 89bio 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is NMRA or ETNB more profitable? 89bio's return on equity of -59.58% beat Neumora Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Neumora TherapeuticsN/A -73.63% -68.97% 89bio N/A -59.58%-52.21% Do institutionals & insiders have more ownership in NMRA or ETNB? 47.7% of Neumora Therapeutics shares are held by institutional investors. 26.4% of Neumora Therapeutics shares are held by insiders. Comparatively, 2.8% of 89bio shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Which has more volatility and risk, NMRA or ETNB? Neumora Therapeutics has a beta of 2.5, indicating that its stock price is 150% more volatile than the S&P 500. Comparatively, 89bio has a beta of 1.17, indicating that its stock price is 17% more volatile than the S&P 500. Does the MarketBeat Community favor NMRA or ETNB? 89bio received 86 more outperform votes than Neumora Therapeutics when rated by MarketBeat users. However, 89.66% of users gave Neumora Therapeutics an outperform vote while only 64.00% of users gave 89bio an outperform vote. CompanyUnderperformOutperformNeumora TherapeuticsOutperform Votes2689.66% Underperform Votes310.34%89bioOutperform Votes11264.00% Underperform Votes6336.00% SummaryNeumora Therapeutics and 89bio tied by winning 8 of the 16 factors compared between the two stocks. Get Neumora Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NMRA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NMRA vs. The Competition Export to ExcelMetricNeumora TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$276.27M$3.12B$5.78B$8.98BDividend YieldN/A1.57%4.78%3.85%P/E Ratio-0.9630.1126.4618.82Price / SalesN/A412.67457.0180.82Price / CashN/A183.5344.0437.47Price / Book0.593.567.634.64Net Income-$235.93M-$71.72M$3.18B$245.69M7 Day Performance3.45%-2.45%-1.82%-2.63%1 Month Performance-12.62%0.36%0.22%-2.37%1 Year Performance-89.99%-11.50%17.49%13.65% Neumora Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NMRANeumora Therapeutics4.0824 of 5 stars$1.80+5.3%$16.50+816.7%-90.0%$276.27MN/A-0.96108News CoverageETNB89bio3.1191 of 5 stars$10.57-1.4%$31.43+197.3%+5.9%$1.12BN/A-3.6340Analyst ForecastGYREGyre Therapeutics0.2947 of 5 stars$11.98+1.7%N/A-18.3%$1.12B$113.45M0.0040AUPHAurinia Pharmaceuticals2.5501 of 5 stars$7.79-2.3%$11.50+47.6%+38.1%$1.12B$175.51M-51.93300Analyst DowngradeNews CoverageNTLAIntellia Therapeutics4.3943 of 5 stars$10.70+11.0%$48.71+355.2%-54.7%$1.09B$36.28M-1.97600News CoverageGap UpMRVIMaravai LifeSciences4.0154 of 5 stars$4.20+1.9%$10.28+144.8%-21.9%$1.06B$288.95M-2.56610Options VolumeNews CoverageGap UpELVNEnliven Therapeutics1.8116 of 5 stars$21.68+0.8%$38.25+76.4%+34.9%$1.06BN/A-11.4150PAHCPhibro Animal Health4.0924 of 5 stars$25.77+2.3%$21.00-18.5%+79.6%$1.04B$1.02B53.691,940Analyst RevisionHigh Trading VolumeZYMEZymeworks2.0962 of 5 stars$15.01+2.7%$19.17+27.7%+22.6%$1.03B$76.01M-10.01460ABCLAbCellera Biologics2.6919 of 5 stars$3.27+4.1%$8.33+154.8%-37.0%$965.86M$38.03M-5.36500Upcoming EarningsREPLReplimune Group4.0934 of 5 stars$14.10-1.3%$19.29+36.8%+83.0%$964.72MN/A-4.62210Gap Up Related Companies and Tools Related Companies 89bio Competitors Gyre Therapeutics Competitors Aurinia Pharmaceuticals Competitors Intellia Therapeutics Competitors Maravai LifeSciences Competitors Enliven Therapeutics Competitors Phibro Animal Health Competitors Zymeworks Competitors AbCellera Biologics Competitors Replimune Group Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:NMRA) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersBuy NVDA Now? After weeks of volatility, did President Trump just turn Nvidia (NVDA) into a raging BUY? The beloved chip...Chaikin Analytics | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredWe recommended Palantir in 2021, now we’re recommending this...I believe it could offer you a MAJOR boost to your retirement. And it pays huge dividends to give you a nic...Behind the Markets | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now...Colonial Metals | SponsoredThis Crypto Is Set to Explode in FebruaryIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neumora Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Neumora Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
